Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
160 studies found for:    rsv
Show Display Options
Rank Status Study
1 Recruiting RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: Saline Placebo (0.5mL injection);   Drug: RSV F vaccine (0.5mL injection)
2 Completed Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01;   Drug: Normal Saline
3 Recruiting Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
Condition: Respiratory Syncytial Virus (RSV)
Interventions: Biological: RSV-F Vaccine;   Biological: Saline Placebo
4 Recruiting RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: PanAd3-RSV given intra-nasally (high dose);   Biological: MVA-RSV given by intra-muscular injection (high dose);   Biological: PanAd3-RSV given by intra-muscular injection (high dose);   Biological: PanAd3-RSV given intranasally (low dose);   Biological: MVA-RSV given by intra-muscular injection (low dose);   Biological: PanAd3-RSV given by intra-muscular injection (low dose)
5 Completed Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01;   Drug: normal saline
6 Not yet recruiting To Evaluate the Safety and Ability of the Medicine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
Condition: Respiratory Syncytial Virus (RSV)
Interventions: Biological: RSV F subunit vaccine-Low dosage; no adjuvant;   Biological: RSV F subunit vaccine-Medium dosage; no adjuvant;   Biological: RSV F subunit vaccine-High dosage; no adjuvant;   Biological: RSV F subunit vaccine-Low dosage; with aluminum hydroxide;   Biological: RSV F subunit vaccine-Medium dosage; with aluminum hydroxide;   Biological: RSV F subunit vaccine-High dosage; with aluminum hydroxide;   Biological: RSV F subunit vaccine-Low dosage; with MF59;   Biological: RSV F subunit vaccine-Medium dosage; with MF59;   Biological: RSV F subunit vaccine-High dosage; with MF59;   Biological: Placebo-Sterile Saline
7 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
8 Completed Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
Condition: RSV Bronchiolitis
Intervention: Drug: Azithromycin
9 Completed Intra-nasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)
Condition: RSV Infection
Interventions: Drug: MEDI-557;   Other: Placebo
10 Active, not recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV cps2 Vaccine;   Biological: Placebo Vaccine
11 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV cps2 Vaccine;   Biological: Placebo Vaccine
12 Completed RSV-F Vaccine Dose Ranging Study in Young Women
Condition: Respiratory Syncytial Virus (RSV)
Interventions: Biological: Low dose RSV-F Vaccine with Adjuvant;   Biological: Low dose RSV-F Vaccine without Adjuvant;   Biological: High dose RSV-F Vaccine with Adjuvant;   Biological: High dose RSV-F Vaccine without Adjuvant;   Biological: Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing];   Biological: Placebo
13 Completed Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study
Conditions: RSV Infection;   Bronchiolitis
Intervention: Other: Collection of exhaled breath
14 Completed RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
Condition: Respiratory Syncytial Virus (RSV)
Interventions: Biological: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28);   Biological: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28);   Biological: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28);   Biological: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28);   Biological: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
15 Completed Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV-F Particle Vaccine;   Biological: Placebo
16 Completed Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
Condition: Respiratory Syncytial Virus Infections
Intervention: Drug: ALN-RSV01
17 Recruiting Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 Vaccine;   Biological: Placebo Vaccine
18 Recruiting Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 Vaccine;   Biological: Placebo Vaccine
19 Active, not recruiting Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines
Condition: Infections, Respiratory Syncytial Virus
Interventions: Biological: RSV vaccine GSK3003892A (formulation 1);   Biological: RSV vaccine GSK3003893A (formulation 2);   Biological: RSV vaccine GSK3003895A (formulation 3);   Biological: RSV vaccine GSK3003896A (formulation 4);   Biological: RSV vaccine GSK3003898A (formulation 5);   Biological: RSV vaccine GSK3003899A (formulation 6);   Drug: Placebo comparator
20 Completed Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to 2009
Condition: Respiratory Syncyctial Virus Vaccines
Intervention: Other: Data collection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years